Metabasis Therapeutics, Inc. Presents Preclinical Results for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia at the American Thyroid Association’s National Meeting

SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that it gave two presentations during the 78th Annual Meeting of the American Thyroid Association in New York, NY. Both provided preclinical data on MB07811, the Company’s clinical-stage liver-targeted, beta-subtype-selective thyroid hormone receptor (TRß) agonist product candidate for the treatment of hyperlipidemia.